Merck Sharp + Dohme Corp.

Mochida Pharmaceutical Co., Ltd.

Dann Parker

Qun Dang

Lihu Yang

Sheo B Singh

David Brian Olsen

Robert R Wilkening

Takashi Mizuno

Jing Su

Dongfang Meng

Cameron James Smith

Takao Suzuki

Jiayi Xu

James M Apgar

Mihir Mandal

Ting Zhang

Katherine Young

Hiroshi Nagasue

Tomokazu Hirabayashi

Yoshitaka Maeda

Isao Sakurada

Ronald E Painter

William K Hagmann

Ravi P Nargund

Mark E Fraley

Hubert B Josien

Bin Hu

Barbara A Pio

Dong-Ming Shen

Craig A Stump

Casey Cameron McComas

Deping Wang

Ping Liu

Chun Sing Li

Bowei Wang

Purakkattle J Biju

Helen J Mitchell

Linus S Lin

Bing Li

Harry R Chobanian

Zhengxia Chen

Andrew John Cooke

Timothy Allen Blizzard

Qinghua Mao

Meibi Dai

Alejandro Crespo

Melody McWherter

Jason W Szewczyk

Xu-Fang Zhang

Meng Yang

Troy McCracken

Jonathan E Wilson

Zack Zhiqiang Guo

Candido Gude

Kathy Schirripa

Mingxiang Cui

Ying Lv

Lili Tian

Zaihong Zhang

Troy Mccracken

The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction. 

Pyrazolyl pyrimidinone compounds as PDE2 inhibitors

The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections byby administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.

Nargenicin compounds and uses thereof as antibacterial agents

In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes. 

Factor IXa inhibitors

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. 

TrKA kinase inhibitors, compositions and methods thereof

The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic substituted heteroaryl compounds

Growing community of inventors

Cranford, NJ, United States of America

Dann Parker